Navigation Links
Chiltern Welcomes Drs. Dieter Seitz-Tutter And Alexandra Adams
Date:9/10/2012

LONDON, Sept. 10, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Dieter Seitz-Tutter and Alexandra Adams have joined Chiltern, bringing their extensive expertise in clinical research to serve our clients' needs and to strengthen our Global Clinical Development service.

"It gives me great pleasure to announce that Dieter Seitz-Tutter, Ph.D. has been appointed to the new role of Vice President, Global Clinical Development, Europe," stated Aize Smink, Sr. Executive VP, Global Clinical Development, Chiltern. "Dr. Seitz-Tutter will lead Chiltern's Global Clinical Development business across Europe, comprising Clinical Operations and Project Management which is experiencing strong growth thanks to deeper client relations and demand for our quality services."

Recently joining Chiltern is Alexandra Adams, Ph.D. as Director, Late Phase, Europe. "Dr. Adams will lead the Global Late Phase Group in Europe which is focused on implementing tailored solutions for late phase studies and registries in a cost effective way on behalf of our client base," commented Steve Albrecht, Global Head, Late Phase, Chiltern.

Dr. Seitz-Tutter has more than 22 years experience in the clinical research field which he gained from various senior roles in both Pharma and CROs, most recently serving as Vice President Europe with a global corporation. Dr. Seitz-Tutter holds a Master's degree and a doctorate in Biology from the University of Munich, Germany, and is also based out of Munich.

Dr. Adams brings 25 years experience from a varied background in both Pharma and CRO positions. Her experience includes developing new procedures and strategies for the implementation of non-interventional studies. Dr. Adams received her Ph.D. in Biochemistry / Pharmacology from the Cardiothoracic Institute at the University of London. She is a long-standing member of the Institute of Clinical Rese
'/>"/>

SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chiltern Announces New Legal Entity In Taiwan
2. United States Rocket Academy Welcomes XCOR Aerospace to Texas
3. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
4. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
5. Cepheid Welcomes Senior Vice President of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... Wins for Industry Leadership, JOPLIN, Mo., Jan. ... announced its Medical Power group has received,Battery Power ... received honors in the Industry Leadership category for ... battery., The Innova Award recognizes companies that ...
... BSX ) today announced that it has completed ... to the Getinge Group of,Sweden for $750 million in ... 5, 2007., The Company expects to record after-tax ... These charges will be recorded,during the fourth quarter of ...
... VICL ) today announced that Vijay Samant, ... panel discussion on biodefense and,pandemic influenza Wednesday evening ... CA - January 7-10)., The session is ... Aldridge LLP.,Co-keynotes for the session are Rajeev Venkayya, ...
Cached Biology Technology:EaglePicher Technologies Receives Battery Power Products and Technology's First Annual Innova Award 2Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 2Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses 3Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference 2
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... If pending clinical trials prove successful, a new ... http://www.fasebj.org ) could represent a major scientific leap toward ... appearing online, Yale scientists provide evidence to support a ... idea that cells added to a graft before implantation ...
... R.I. [Brown University] Aggregating nearly the entire landmass of ... not seen for the last 200 million years. Its size ... roam, for there were few geographical barriers, such as mountains ... confined themselves. Studying a transect of Pangaea stretching from about ...
... This release is available in German . ... Muscle contractions are the basis of all movements, at least ... don,t have any muscles at all, as they branched off ... animal groups, for instance the sea sponges, are not immovable. ...
Cached Biology News:Yale scientists discover new method for engineering human tissue regeneration 2Latitude and rain dictated where species lived 2Latitude and rain dictated where species lived 3Movement without muscles 2
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: